US Biotech Stocks: Leading US Biotech Companies in 2026
The US biotech sector remains driven by new drug development, regulatory approvals and dealmaking. By 13th August 2026, the FDA had approved 32 novel drugs, while biotech M&A activity also accelerated during the year. These developments highlight the continued pace of innovation across oncology, rare diseases, immunology and gene-based therapies.
US Biotech Stocks - List of US Biotech Stocks 2026
Showing 1 - 20 of 609 results
last updated at 8:30 AM IST
| NameUS Stocks (609)↓ | ↓Sub-SectorSub-Sector↓ | ↓Market CapMarket Cap↓ | ↓Close PriceClose Price↓ | ↓PE Ratio (TTM)PE Ratio (TTM)↓ | ↓1M Return1M Return↓ | ↓1D Return1D Return↓ | ↓Return on EquityReturn on Equity↓ | ↓PB RatioPB Ratio↓ | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals IncVRTX | BiotechnologyBiotechnology | 1,10,641.401,10,641.40 | 508.34508.34 | 29.9529.95 | -3.76-3.76 | -1.56-1.56 | 23.5423.54 | 6.446.44 | |
| 2. | Regeneron Pharmaceuticals IncREGN | BiotechnologyBiotechnology | 66,532.9566,532.95 | 784.85784.85 | 19.1619.16 | -3.13-3.13 | -0.62-0.62 | 14.0414.04 | 2.512.51 | |
| 3. | argenx NV ADRARGX | BiotechnologyBiotechnology | 51,218.6951,218.69 | 995.77995.77 | 37.5737.57 | 0.280.28 | -0.59-0.59 | 23.6423.64 | 7.287.28 | |
| 4. | Alnylam Pharmaceuticals IncALNY | BiotechnologyBiotechnology | 39,452.9739,452.97 | 245.51245.51 | 41.4841.48 | 7.397.39 | -2.46-2.46 | 96.5696.56 | 23.5523.55 | |
| 5. | Revolution Medicines IncRVMD | BiotechnologyBiotechnology | 32,469.8432,469.84 | 190.95190.95 | -- | -11.60-11.60 | -3.01-3.01 | -79.09-79.09 | 16.8816.88 | |
| 6. | BeiGene, Ltd.ONC | BiotechnologyBiotechnology | 31,378.5231,378.52 | 350.84350.84 | 62.1662.16 | -4.96-4.96 | -0.74-0.74 | 14.6614.66 | 7.587.58 | |
| 7. | Royalty Pharma PlcRPRX | BiotechnologyBiotechnology | 31,014.3231,014.32 | 58.4158.41 | 31.4431.44 | -2.14-2.14 | -0.85-0.85 | 13.9713.97 | 3.813.81 | |
| 8. | BioNTech SEBNTX | BiotechnologyBiotechnology | 23,644.6823,644.68 | 98.6698.66 | -- | 6.376.37 | -2.59-2.59 | -9.30-9.30 | 1.181.18 | |
| 9. | Insmed IncINSM | BiotechnologyBiotechnology | 23,062.4623,062.46 | 123.98123.98 | -- | -3.49-3.49 | -3.26-3.26 | -87.22-87.22 | 35.3435.34 | |
| 10. | Roivant Sciences LtdROIV | BiotechnologyBiotechnology | 21,427.0721,427.07 | 39.7739.77 | -- | 6.426.42 | -0.45-0.45 | -8.52-8.52 | 6.746.74 | |
| 11. | Incyte CorporationINCY | BiotechnologyBiotechnology | 19,398.8519,398.85 | 127.62127.62 | 15.5015.50 | 3.363.36 | -1.79-1.79 | 30.6730.67 | 3.893.89 | |
| 12. | Moderna IncMRNA | BiotechnologyBiotechnology | 18,660.8618,660.86 | 154.04154.04 | -- | 144.66144.66 | -2.57-2.57 | -39.00-39.00 | 8.498.49 | |
| 13. | Genmab ASGMAB | BiotechnologyBiotechnology | 16,398.1816,398.18 | 34.5334.53 | 26.8826.88 | 4.784.78 | 0.580.58 | 14.0014.00 | 3.523.52 | |
| 14. | Jazz Pharmaceuticals PLCJAZZ | BiotechnologyBiotechnology | 14,895.7714,895.77 | 243.84243.84 | 16.4716.47 | -3.65-3.65 | -1.24-1.24 | 22.1122.11 | 3.263.26 | |
| 15. | Ascendis Pharma ASASND | BiotechnologyBiotechnology | 14,699.5714,699.57 | 239.04239.04 | 19.1619.16 | -3.94-3.94 | -0.85-0.85 | 118.78118.78 | 9.479.47 | |
| 16. | BridgeBio Pharma IncBBIO | BiotechnologyBiotechnology | 13,537.9313,537.93 | 67.3167.31 | -- | -18.88-18.88 | -1.07-1.07 | -1,789.67-1,789.67 | 123.68123.68 | |
| 17. | Summit Therapeutics PLCSMMT | BiotechnologyBiotechnology | 13,318.9513,318.95 | 17.8517.85 | -- | 39.2439.24 | 0.730.73 | -192.51-192.51 | 22.0522.05 | |
| 18. | Ionis Pharmaceuticals IncIONS | BiotechnologyBiotechnology | 12,725.2212,725.22 | 46.7546.75 | -- | -21.57-21.57 | -4.95-4.95 | -105.50-105.50 | 17.8617.86 | |
| 19. | Exelixis IncEXEL | BiotechnologyBiotechnology | 12,562.7312,562.73 | 58.4958.49 | 17.9117.91 | 10.1110.11 | -0.26-0.26 | 44.3944.39 | 7.647.64 | |
| 20. | Madrigal Pharmaceuticals IncMDGL | BiotechnologyBiotechnology | 12,145.4912,145.49 | 531.52531.52 | -- | 1.361.36 | -0.55-0.55 | -53.31-53.31 | 23.1123.11 |
Disclaimer: Please note that the above table is for informational purposes only, and is not recommendatory. Please do your own research or consult your financial advisor before investing. The data is derived from Tickertape Stock Screener and is subject to real-time updates.
Overviews of US Biotech Stocks
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a biotechnology company best known for treatments targeting serious genetic diseases, particularly cystic fibrosis. Its portfolio also extends into pain management, sickle cell disease and other speciality areas. The company invests heavily in research and development, with growth influenced by new drug launches, pipeline progress and regulatory approvals.
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals develops and commercialises medicines across eye diseases, oncology, immunology and rare conditions. Its major products include Eylea and Dupixent, alongside a broad clinical pipeline. The company’s performance is influenced by prescription growth, competition, patent protection, regulatory approvals and the commercial success of new and existing therapies.
argenx NV ADR
argenx is a biotechnology company focused on treatments for severe autoimmune diseases. Its lead therapy, Vyvgart, targets conditions driven by pathogenic antibodies and has expanded into multiple indications. Growth depends on wider adoption of Vyvgart, geographic expansion, additional regulatory approvals and progress across the company’s pipeline of immune-focused therapies.
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals specialises in RNA interference (RNAi) therapeutics designed to silence disease-causing genes. Its commercial portfolio targets rare and cardiometabolic diseases, including transthyretin amyloidosis. The company’s growth is linked to patient adoption, label expansions, pipeline development and broader acceptance of RNAi-based treatments across additional disease categories.
Revolution Medicines Inc
Revolution Medicines is a clinical-stage oncology company developing targeted therapies for cancers driven by RAS mutations. Its pipeline includes experimental treatments aimed at difficult-to-target KRAS and related pathways. Company performance is closely tied to clinical trial results, regulatory progress, development timelines and the potential commercial opportunity for its oncology candidates.
What are US Biotech Stocks?
US biotech stocks represent publicly listed biotechnology companies developing medicines and therapies using biological processes, genetics and advanced research. These companies may focus on areas such as oncology, rare diseases, immunology and gene-based treatments. Their performance is often influenced by clinical trial results, regulatory approvals, drug launches and research pipelines.
How to Evaluate and Invest in US Biotech Sector Stocks?
Here's how to invest in the US biotech stock market from India, step by step:
- Log in or Create an Account: Visit Tickertape US Stocks and log in to your account. Create an account if you have not registered yet and complete the US investing account-opening process.
- Search for Biotech Stocks: Use the Tickertape US Stock Screener and select 'Biotechnology' under the sector filter.
- Analyse the Stocks: Each stock page provides information such as the live market price, 52-week range, financial performance, peer comparison and recent news.
- Add Money to Your US Wallet: Connect an eligible bank account and transfer money to your US Wallet under the Liberalised Remittance Scheme.
- Place Your Order: Select the biotech stock you want to invest in and click on 'Buy' to place the order through Tickertape.
Taxation of US Biotech Stocks for Indian Investors
For Indian investors, returns from US biotech stocks may have tax implications in India and the US. Capital gains and dividends are taxed differently, while resident investors may also need to disclose foreign investments and income when filing their Indian income tax returns.
| Income / Action | Holding Period / Condition | Tax Rate in the US | Tax Rate in India |
|---|---|---|---|
| Long-Term Capital Gains (LTCG) | Held for > 24 months | 0% (Taxed only in India under DTAA) | 12.5% (+ applicable surcharge & cess) |
| Short-Term Capital Gains (STCG) | Held for < 24 months | 0% (Taxed only in India under DTAA) | Taxed as per your applicable income slab rate |
Advantages of Investing in US Biotech Stocks
Innovation Exposure
US biotech stocks provide exposure to emerging areas such as RNAi, gene therapies, precision oncology and autoimmune treatments that may create new therapeutic markets.
Approval Upside
Successful regulatory approvals can materially expand a company’s addressable market. The FDA approved 32 novel drugs by mid-August 2026 alone.
Acquisition Potential
Large pharmaceutical companies often acquire biotech firms for promising pipelines. 38 biotech acquisitions had already been announced by the first half of 2026.
Diverse Niches
Biotech companies operate across oncology, rare diseases, immunology, neurology, and cardiometabolic treatments, allowing exposure to diverse medical needs rather than a single end-market.
Pipeline Growth
Biotech value can come from multiple clinical programmes rather than existing sales alone, particularly when companies successfully progress candidates into later-stage trials.
Capital Recovery
Thirteen biotech companies raised about $4.5 bn through US IPOs in 2026, indicating improved access to capital markets compared with the weak 2025 environment.
Receive real-time market alerts for timely decisions
Monitor your portfolio from the palm of your hands
Watchlist stocks and mutual funds to stay updated
Risks of Investing in US Biotech Stocks
Trial Failure
A negative clinical trial can significantly reduce a biotech company’s future revenue potential, particularly when its valuation depends heavily on one or two experimental drugs.
Regulatory Uncertainty
FDA review standards remain an important risk. Industry leaders in 2026 highlighted concerns around consistency, particularly for rare-disease and expedited approval pathways.
Funding Dependence
Many pre-revenue biotech companies rely on external capital. In H1 2026, 76% of venture funding came from $100 mn-plus rounds, showing capital remained concentrated.
Commercialisation Risk
Approval does not guarantee commercial success. Drug uptake can still depend on pricing, reimbursement, competing therapies, physician adoption and the size of the eligible patient population.
Factors to Consider Before Investing in US Biotech Stocks
Clinical Milestones
Investors can track trial phases, enrolment progress, and primary endpoints, as successful Phase II or III data can materially change a biotech company’s commercial prospects.
Cash Runway
For loss-making biotech companies, investors can assess cash balances against quarterly spending to gauge how long operations can continue before additional financing is required.
Pipeline Concentration
Companies dependent on a single lead therapy may face greater company-specific risk than those with several clinical candidates, indications, or already commercialised products.
Regulatory Calendar
PDUFA dates, FDA decisions and label expansions can act as major catalysts. By 13 August 2026, 32 novel drugs had received FDA approval.
Market Opportunity
Investors can examine eligible patient populations, treatment alternatives and reimbursement conditions because a scientifically successful drug may still address only a limited commercial market.
Key Growth Drivers for US Biotech Stocks
Drug Innovation
IQVIA expects 70–80 novel active substances to launch each year globally through 2030, supporting continued pipeline development across oncology, rare diseases, and immunology.
US Clinical Activity
Clinical trial starts increased among US-headquartered sponsors in 2025, reinforcing the country’s role in developing new medicines and expanding biotech pipelines.
FDA Approvals
The FDA had approved 32 novel drugs by 13 August 2026, creating commercial opportunities for companies successfully moving therapies from clinical development to market.
M&A Activity
Biotech dealmaking accelerated in 2026, with 38 acquisitions announced by mid-year, the sector’s fastest acquisition pace in at least seven years.
AI-led R&D
IQVIA reports early evidence of improved success rates in AI-enabled programmes, suggesting that artificial intelligence could help biotech companies improve the efficiency of drug discovery and development.
How to Track US Biotech Stocks From India on Tickertape?
You can track US biotech stocks and ETFs from India on Tickertape’s US Stocks & ETFs platform.
- Open US Stocks Screener: Visit the Tickertape US Stock Screener and explore biotech-related companies listed on US exchanges.
- Search Biotech Stocks: Search for “Biotechnology” under the sector and select it to explore companies operating in the biotech industry.
- Apply Filters: Compare companies using 60+ parameters, including market capitalisation, valuation ratios, profitability metrics, growth indicators and financial health measures.
- Analyse Company Metrics: Review individual stock pages to understand financial performance, revenue trends, margins, debt levels, price movements and other available insights.
- Create a Watchlist: Add selected biotech stocks to your watchlist to track price updates, company developments and performance changes from India.
Conclusion
US biotech stocks offer exposure to drug innovation, clinical pipelines and emerging treatment technologies, but performance can vary sharply with trial results, FDA decisions, funding needs and commercial execution. Investors can use the Tickertape US Stock Screener with 60+ filters to compare biotech stocks across valuation, growth, profitability, financial health and other key metrics before conducting further research.
Popular US Stock Collections
Popular Indian Mutual Fund Collections
Frequently Asked Questions on US Biotech Stocks
What are US Biotech Stocks?
US biotech stocks are shares of publicly listed biotechnology and biopharmaceutical stocks developing medicines, diagnostics and advanced therapies across areas such as oncology, rare diseases, immunology, gene therapy and RNA-based treatments.Which top companies are included in US Biotech Stocks?
The following are the best US biotech companies based on 1Y returns as of 14th August, 2026:
Disclaimer: Please note that the above US Biotech stocks list is for educational purposes only, and is not recommendatory. Please conduct your own research or consult with your financial advisor before investing.What is the outlook for US Biotech Stocks in 2026?
The NASDAQ Biotech Index tracks many major biotechnology companies and reflects sector trends. In 2026, the industry remains driven by FDA approvals, clinical milestones, M&A activity and improving capital-market access. Disclaimer: Market outlooks can change due to economic conditions, regulations and company-specific factors. This information is for educational purposes only and should not be considered investment advice.Are Biotech US Stocks considered risky for Indian investors?
Yes, biotech stocks can be volatile because valuations often depend on clinical trial results, regulatory approvals and funding needs. Indian investors also face USD-INR currency movements and overseas taxation considerations. Disclaimer: Risk levels vary across companies and depend on individual financial circumstances. Investors should conduct their own research before making investment decisions.What is the difference between individual US Biotech stocks and Biotech-focused ETFs?
Individual companies from a biotech stocks list carry company-specific risks linked to particular drugs or pipelines. Biotech-focused ETFs spread exposure across multiple companies, reducing dependence on a single clinical outcome. Disclaimer: This information is for educational purposes only and does not constitute investment advice or a recommendation to buy, hold or sell any security.How can I compare US Biotech Stocks on Tickertape?
Investors can compare US biotech stocks using the Tickertape US Stock Screener with 60+ filters covering valuation, growth, profitability, financial health and other company-level metrics.Can beginners invest in US Biotech Stocks?
Beginners can access the best US biotech stocks, but understanding clinical pipelines, cash runway, FDA timelines and commercial products is important because biotech companies can differ substantially in risk and maturity. Disclaimer:Whether an investment is suitable depends on an investor’s financial goals, risk appetite and research. This content is for educational purposes only.How to invest in US Biotech Stocks?
Investors can invest in US Biotech stocks from India through a regulated platform like Tickertape. The process generally involves:
- Create a US investing account: Log in to Tickertape, visit the US Stocks section and start the account-opening process.
- Select Biotech stocks: Explore Biotech-related companies and compare available stocks.
- Complete KYC: Complete digital verification using DigiLocker or submit the required documents.
- Connect your bank account: Link an eligible bank account for remittances under the Liberalised Remittance Scheme (LRS).
- Add funds: Transfer money to your US investing account.
- Invest: Select a Biotech stock and place an order. Some platforms may allow fractional investing from $1.
What metrics are commonly used to evaluate US Biotech Stocks?
When analysing the US biotech sector, investors commonly examine revenue growth, R&D spending, cash runway, pipeline stages, trial results, regulatory timelines, profitability and dependence on individual products.
Disclaimer: The metrics mentioned are for educational purposes only and do not indicate the quality or suitability of any stock. Investors should evaluate companies based on their individual financial goals and risk profile.Do US Biotech stocks pay dividends?
Some established biopharmaceutical stocks may pay dividends, but many biotech companies reinvest cash into research, clinical trials and drug development. Dividend policies therefore vary significantly across the sector.
Disclaimer: Dividend payments are not guaranteed and may change based on company decisions and market conditions. Past dividend history does not indicate future dividend payments.
